| MicroRNA |
170 |
| Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management |
167 |
| Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis |
81 |
| Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb |
72 |
| Atopic dermatitis endotypes and implications for targeted therapeutics |
69 |
| Obesity and asthma |
67 |
| Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy |
52 |
| Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects |
51 |
| Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison |
51 |
| Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study |
51 |
| Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema |
45 |
| Oral corticosteroid exposure and adverse effects in asthmatic patients |
42 |
| Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma |
42 |
| The microbiome in patients with atopic dermatitis |
41 |
| Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab |
40 |
| Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology |
39 |
| Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study |
38 |
| Early-onset pediatric atopic dermatitis is characterized by T(H)2/T(H)17/T(H)22-centered inflammation and lipid alterations |
35 |
| Itch: From mechanism to (novel) therapeutic approaches |
34 |
| The atopic march and atopic multimorbidity: Many trajectories, many pathways |
34 |
| Phenotypes and endotypes of adult asthma: Moving toward precision medicine |
34 |
| Inflammatory health effects of indoor and outdoor particulate matter |
34 |
| Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study |
33 |
| Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes |
33 |
| Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology |
31 |
| Epigenome-wide meta-analysis of DNA methylation and childhood asthma |
31 |
| Endotype-driven care pathways in patients with chronic rhinosinusitis |
31 |
| Mast cells signal their importance in health and disease |
31 |
| Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation |
29 |
| GBR an anti-OX improves skin gene signatures and clinical scores in patients with atopic dermatitis |
29 |
| Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease |
29 |
| Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study |
28 |
| Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids |
28 |
| External exposome and allergic respiratory and skin diseases |
28 |
| Intestinal microbiota in infants at high risk for allergy: Effects of prebiotics and role in eczema development |
28 |
| Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry |
28 |
| Association between the intestinal microbiota and allergic sensitization, eczema, and asthma: A systematic review |
27 |
| Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease |
27 |
| Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy |
27 |
| Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology |
27 |
| Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: The role of thymic stromal lymphopoietin |
27 |
| Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab |
26 |
| Efficacy and safety of the histamine H-4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis |
26 |
| Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles |
26 |
| X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability |
25 |
| Report from the National Institute of Allergy and Infectious Diseases workshop on Atopic dermatitis and the atopic march: Mechanisms and interventions'' |
25 |
| IL-31: A new key player in dermatology and beyond |
25 |
| Identification of galectin-3 as an autoantigen in patients with IgG(4)-related disease |
25 |
| Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients |
25 |
| Mechanisms of food allergy |
25 |
